3 billion antihypertensive drug big varieties to meet the first evaluation of the original research drug "lost" 70% of the market

The basic situation of medicine
the original development agent of the boson capsule (80mg) for novartis "devin" of Switzerland, the indications for the treatment of light and moderate primary hypertensionThe drug belongs to the blood pressure reduction drug of angiotensin II receptor antagonist class, is one of the most widely used blood pressure-lowering drugs in the domestic market, and is listed as a class A drug in the new edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Series, released in August 20192018 China's public medical institutions terminal shattan capsule brand patternmeternet data show that in 2018 in China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal satan capsule sales of up to 3.723 billion yuan, the main manufacturers are Novartis, Changzhou Four Pharmaceuticals, Huarun Saike Pharmaceuticals, Lizhu Group Pearl Pharmaceuticals and other pharmaceuticalIt is worth noting that in recent years, with the development of domestic pharmaceutical companies, Novartis's market share has gradually declined, from 75.07 percent in 2013 to 66.81 percent in 2018Lepu Medical said that the company in September 2016 to Lepu Heng long-standing realization of holding, and actively promote the "Shatan capsule" consistency evaluation work, currently Lepu Heng long for the species of the first domestic through the consistency evaluation of the enterpriseThe company will actively respond to the national health care reform policy, and with the help of the brand advantages in the field of cardiovascular, to play the synergy of lepu marketing network, to achieve the rapid release of the drug-meter net white feather finishingsource: listed company announcement, minet database